Blueprint Medicines Corp Income Statement

Ask AI

Financial Statements

In millions of USD; shares in millions, except per-share amounts

	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021	FY2020 12 months to Dec 31, 2020
Revenue
Product revenue, net
Collaboration revenue
Collaboration and license revenue
License revenue - related party
Total collaboration and license revenue
Total collaboration revenue

Total revenue
Cost and operating expenses:
Cost of sales
Research and development
Selling, general and administrative
Collaboration loss sharing
Total cost and operating expenses
Other income (expense):
Interest expense, net
Other income (expense), net
Debt extinguishment gain
Total other income (expense)
Loss before income taxes
Income tax expense
Net loss
Other comprehensive income (loss):
Unrealized gain (loss) on pension benefit obligations
Unrealized gain (loss) on available-for-sale investments
Currency translation adjustments
Comprehensive loss
Net loss per share - basic (in dollars per share)
Net loss per share - diluted (in dollars per share)
Weighted-average number of common shares used in net loss per share - basic (in shares)
Weighted-average number of common shares used in net loss per share - diluted (in shares)

Comments